Home › Companies › KEROS THERAPEUTICS INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and KEROS THERAPEUTICS INC.’s Form 8-K, filed June 9, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 4, 2025: 5 items on KEROS THERAPEUTICS INC.’s Form 8-K, filed June 9, 2025: 3 elected · 2 approved.
Significant dissent: 2 directors (42.2%, 36.4% against).
Notable dissent: 1 director (18.9% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Nantahala Capital (13F, 7.6%, as of September 30, 2026)
Explore KEROS THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are KEROS THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 9, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Mary Ann Gray, Ph.D. | 13,703,361 | -- | -- | 10,006,911 | 4,297,008 | 58% | Elected | — |
| Elect Director: Ran Nussbaum | 22,703,180 | -- | -- | 5,304,100 | 4,297,008 | 81% | Elected | — |
| Elect Director: Alpna Seth, Ph.D. | 15,091,438 | -- | -- | 8,618,834 | 4,297,008 | 64% | Elected | — |
| 2. Ratification of the Selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2025 | 26,436,418 | 217,655 | 855,774 | -- | -- | 99.2% | Approved | — |
| 3. Advisory Vote on Executive Compensation | 18,580,618 | 4,166,083 | 963,571 | -- | 4,297,008 | 82% | Approved | — |
Source: KEROS THERAPEUTICS INC., Form 8-K, filed with the SEC on June 9, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
153 asset managers disclosed a vote on at least one KEROS THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 2 wordings of this item as funds reported it.
64% Majority: yes · of votes cast
Description as filed by funds: To elect the three (3) nominees for Class II director named below to hold office until the 2028 Annual Meeting of Stockholders: Alpna Seth, Ph.D.
KEROS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Alpna Seth, Ph.D.”): 15,091,438 for, 8,618,834 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The Company's stockholders elected the three persons listed below as directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 64% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 48 asset managers below reported 6,891,649 for, 1,233,857 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,522,533 | 0 | 0 | 0 | For |
| BlackRock | 1,173,721 | 0 | 0 | 0 | For |
| Federated Hermes | 1,165,882 | 0 | 0 | 0 | For |
| Fidelity | 715,367 | 0 | 0 | 433,653 | Mixed |
| State Street | 665,314 | 0 | 0 | 1,552 | For |
| ACAP Strategic Fund | 0 | 0 | 0 | 419,586 | Withhold |
| Charles Schwab | 241,835 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 0 | 0 | 0 | 120,198 | Withhold |
| Legg Mason | 111,700 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 0 | 83,163 | Withhold |
| Equitable | 52,247 | 0 | 0 | 28,510 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 50,844 | 0 | 0 | 0 | For |
| Lincoln Financial | 24,800 | 0 | 0 | 20,481 | Mixed |
| Guardian Variable Products Trust | 26,000 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 24,500 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 22,978 | Withhold |
| Goldman Sachs | 21,361 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 19,481 | Withhold |
| Global X | 19,447 | 0 | 0 | 0 | For |
| Northern Trust | 17,832 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 16,589 | Withhold |
| ALPS ETF Trust | 0 | 0 | 0 | 12,693 | Withhold |
| T. Rowe Price | 0 | 0 | 0 | 12,145 | Withhold |
| John Hancock | 0 | 0 | 0 | 11,429 | Withhold |
| JPMorgan | 9,589 | 0 | 0 | 0 | For |
Showing the 25 largest of 48 asset managers. All 48 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
58% Majority: yes · of votes cast
Description as filed by funds: To elect the three (3) nominees for Class II director named below to hold office until the 2028 Annual Meeting of Stockholders: Mary Ann Gray, Ph.D.
KEROS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mary Ann Gray, Ph.D.”): 13,703,361 for, 10,006,911 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The Company's stockholders elected the three persons listed below as directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 58% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 48 asset managers below reported 6,891,649 for, 1,233,857 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,522,533 | 0 | 0 | 0 | For |
| BlackRock | 1,173,721 | 0 | 0 | 0 | For |
| Federated Hermes | 1,165,882 | 0 | 0 | 0 | For |
| Fidelity | 715,367 | 0 | 0 | 433,653 | Mixed |
| State Street | 665,314 | 0 | 0 | 1,552 | For |
| ACAP Strategic Fund | 0 | 0 | 0 | 419,586 | Withhold |
| Charles Schwab | 241,835 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 0 | 0 | 0 | 120,198 | Withhold |
| Legg Mason | 111,700 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 0 | 83,163 | Withhold |
| Equitable | 52,247 | 0 | 0 | 28,510 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 50,844 | 0 | 0 | 0 | For |
| Lincoln Financial | 24,800 | 0 | 0 | 20,481 | Mixed |
| Guardian Variable Products Trust | 26,000 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 24,500 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 22,978 | Withhold |
| Goldman Sachs | 21,361 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 19,481 | Withhold |
| Global X | 19,447 | 0 | 0 | 0 | For |
| Northern Trust | 17,832 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 16,589 | Withhold |
| ALPS ETF Trust | 0 | 0 | 0 | 12,693 | Withhold |
| T. Rowe Price | 0 | 0 | 0 | 12,145 | Withhold |
| John Hancock | 0 | 0 | 0 | 11,429 | Withhold |
| JPMorgan | 9,589 | 0 | 0 | 0 | For |
Showing the 25 largest of 48 asset managers. All 48 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
81% Majority: yes · of votes cast
Description as filed by funds: To elect the three (3) nominees for Class II director named below to hold office until the 2028 Annual Meeting of Stockholders: Ran Nussbaum
KEROS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Ran Nussbaum”): 22,703,180 for, 5,304,100 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The Company's stockholders elected the three persons listed below as directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 48 asset managers below reported 6,874,603 for, 1,250,903 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,522,533 | 0 | 0 | 0 | For |
| BlackRock | 1,173,721 | 0 | 0 | 0 | For |
| Federated Hermes | 1,165,882 | 0 | 0 | 0 | For |
| Fidelity | 715,367 | 0 | 0 | 433,653 | Mixed |
| State Street | 666,100 | 0 | 0 | 766 | For |
| ACAP Strategic Fund | 0 | 0 | 0 | 419,586 | Withhold |
| Charles Schwab | 241,835 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 0 | 0 | 0 | 120,198 | Withhold |
| Legg Mason | 111,700 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 0 | 83,163 | Withhold |
| Equitable | 52,247 | 0 | 0 | 28,510 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 50,844 | 0 | 0 | 0 | For |
| Lincoln Financial | 24,800 | 0 | 0 | 20,481 | Mixed |
| Guardian Variable Products Trust | 26,000 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 24,500 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 22,978 | Withhold |
| Goldman Sachs | 21,361 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 19,481 | Withhold |
| Global X | 19,447 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 0 | 17,832 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 16,589 | Withhold |
| ALPS ETF Trust | 0 | 0 | 0 | 12,693 | Withhold |
| T. Rowe Price | 0 | 0 | 0 | 12,145 | Withhold |
| John Hancock | 0 | 0 | 0 | 11,429 | Withhold |
| JPMorgan | 9,589 | 0 | 0 | 0 | For |
Showing the 25 largest of 48 asset managers. All 48 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
82% Approved · of votes cast
Prior year: 99.4% for (May 30, 2024 meeting) ▼ 17.7 pts
Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the accompanying Proxy Statement.
KEROS THERAPEUTICS INC.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 18,580,618 for, 4,166,083 against — passed, per its Form 8-K filed June 9, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Advisory Vote on Executive Compensation The Company's stockholders approved, on a non-binding advisory basis, Proposal 3.”
Support: 82% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of KEROS THERAPEUTICS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “APPROVAL OF COMPENSATION OF EXECUTIVE OFFICERS” (4 managers, 187,500 for, 928,657 against); “Advisory Vote to Ratify Named Executive Officers' Compensation” (4 managers, 27,572 for, 26,505 against).
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,522,533 | 0 | 0 | 0 | For |
| BlackRock | 1,173,721 | 0 | 0 | 0 | For |
| Federated Hermes | 1,165,882 | 0 | 0 | 0 | For |
| Fidelity | 1,149,020 | 0 | 0 | 0 | For |
| State Street | 666,866 | 0 | 0 | 0 | For |
| ACAP Strategic Fund | 419,586 | 0 | 0 | 0 | For |
| Charles Schwab | 241,835 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 120,198 | 0 | 0 | 0 | For |
| Legg Mason | 111,700 | 0 | 0 | 0 | For |
| TIAA | 0 | 83,163 | 0 | 0 | Against |
| Equitable | 80,757 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 50,844 | 0 | 0 | 0 | For |
| Lincoln Financial | 44,804 | 477 | 0 | 0 | For |
| Guardian Variable Products Trust | 26,000 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 24,500 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 22,978 | 0 | 0 | 0 | For |
| Goldman Sachs | 21,361 | 0 | 0 | 0 | For |
| ProShares | 19,481 | 0 | 0 | 0 | For |
| Global X | 19,447 | 0 | 0 | 0 | For |
| Northern Trust | 17,832 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 16,589 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 12,693 | 0 | 0 | 0 | For |
| T. Rowe Price | 12,145 | 0 | 0 | 0 | For |
| John Hancock | 11,429 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 9,589 | 0 | 0 | Against |
Fund voting reports, all 48 managers: 8,025,264 for, 100,242 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 0 | 2,512,823 | 0 | 0 | Against |
| Logos Global Management LP | 0 | 2,000,000 | 0 | 0 | Against |
| Nantahala Capital Management, LLC | 1,357,370 | 0 | 0 | 0 | For |
| State Street | 1,239,443 | 0 | 0 | 0 | For |
| BlackRock | 1,208,670 | 0 | 0 | 0 | For |
| Federated Hermes | 1,187,232 | 0 | 0 | 0 | For |
| DE Shaw | 1,112,605 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 1,018,734 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 806,375 | 0 | 0 | 0 | For |
| Redmile Group, LLC | 552,506 | 0 | 0 | 0 | For |
| Fidelity | 441,913 | 0 | 0 | 0 | For |
| ALKEON CAPITAL MANAGEMENT LLC | 258,152 | 0 | 0 | 0 | For |
| Charles Schwab | 241,857 | 0 | 0 | 0 | For |
| Northern Trust | 221,569 | 0 | 0 | 0 | For |
| Point72 | 190,297 | 0 | 0 | 0 | For |
| TFG Asset Management GP Ltd | 183,000 | 0 | 0 | 0 | For |
| Western Standard LLC | 158,433 | 0 | 0 | 0 | For |
| Clearbridge Investments, LLC | 143,914 | 0 | 0 | 0 | For |
| DAFNA Capital Management LLC | 130,316 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 121,556 | 0 | 0 | 0 | For |
| Stonepine Capital Management, LLC | 111,900 | 0 | 0 | 0 | For |
| Connor, Clark & Lunn Investment Management Ltd. | 109,585 | 0 | 0 | 0 | For |
| PFM Health Sciences, LP | 104,323 | 0 | 0 | 0 | For |
| Rangeley Capital, LLC | 0 | 85,716 | 0 | 0 | Against |
| Nuveen | 0 | 84,371 | 0 | 0 | Against |
Institutional-manager reports, all 115 managers: 11,628,059 for, 4,727,924 against. Showing the 25 largest; every one is in the interactive database (link above).
99.2% Approved · of votes cast
Prior year: 100.0% for (May 30, 2024 meeting) ▼ 0.8 pts
Description as filed by funds: TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF DELOITTE & TOUCHE LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2025.
KEROS THERAPEUTICS INC.’s own tally for this item (“2. Ratification of the Selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2025”): 26,436,418 for, 217,655 against — passed, per its Form 8-K filed June 9, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Ratification of the Selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2025 The Company's stockholders approved Proposal 2.”
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 48 asset managers below reported 8,125,506 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,522,533 | 0 | 0 | 0 | For |
| BlackRock | 1,173,721 | 0 | 0 | 0 | For |
| Federated Hermes | 1,165,882 | 0 | 0 | 0 | For |
| Fidelity | 1,149,020 | 0 | 0 | 0 | For |
| State Street | 666,866 | 0 | 0 | 0 | For |
| ACAP Strategic Fund | 419,586 | 0 | 0 | 0 | For |
| Charles Schwab | 241,835 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 120,198 | 0 | 0 | 0 | For |
| Legg Mason | 111,700 | 0 | 0 | 0 | For |
| TIAA | 83,163 | 0 | 0 | 0 | For |
| Equitable | 80,757 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 50,844 | 0 | 0 | 0 | For |
| Lincoln Financial | 45,281 | 0 | 0 | 0 | For |
| Guardian Variable Products Trust | 26,000 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 24,500 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 22,978 | 0 | 0 | 0 | For |
| Goldman Sachs | 21,361 | 0 | 0 | 0 | For |
| ProShares | 19,481 | 0 | 0 | 0 | For |
| Global X | 19,447 | 0 | 0 | 0 | For |
| Northern Trust | 17,832 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 16,589 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 12,693 | 0 | 0 | 0 | For |
| T. Rowe Price | 12,145 | 0 | 0 | 0 | For |
| John Hancock | 11,429 | 0 | 0 | 0 | For |
| JPMorgan | 9,589 | 0 | 0 | 0 | For |
Showing the 25 largest of 48 asset managers. All 48 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 40,562,047 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 6.22% |
| 2 | BlackRock | 2.89% |
| 3 | Federated Hermes | 2.87% |
| 4 | Fidelity | 2.83% |
| 5 | State Street | 1.64% |
| 6 | ACAP Strategic Fund | 1.03% |
| 7 | Charles Schwab | 0.60% |
| 8 | Advantage Advisers Xanthus Fund, L.L.C. | 0.30% |
| 9 | Legg Mason | 0.28% |
| 10 | TIAA | 0.21% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | ADAR1 Capital Management, LLC | 6.20% |
| 2 | Logos Global Management LP | 4.93% |
| 3 | Nantahala Capital Management, LLC | 3.35% |
| 4 | State Street | 3.06% |
| 5 | BlackRock | 2.98% |
| 6 | Federated Hermes | 2.93% |
| 7 | DE Shaw | 2.74% |
| 8 | ORBIMED ADVISORS LLC | 2.51% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 1.99% |
| 10 | Redmile Group, LLC | 1.36% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Entities affiliated with ADAR1 | 5,390,964 | 13.29% | Proxy statement (DEF 14A), proxy filed April 23, 2025 |
| Ran Nussbaum | 4,823,917 | 11.89% | Proxy statement (DEF 14A), proxy filed April 23, 2025 |
| Tomer Kariv | 4,823,917 | 11.89% | Proxy statement (DEF 14A), proxy filed April 23, 2025 |
| Entities affiliated with Pontifax | 4,787,331 | 11.80% | Proxy statement (DEF 14A), proxy filed April 23, 2025 |
| BlackRock | 2,785,237 | 6.87% | Form 13F, quarter ended March 31, 2025 |
| Madison Avenue Partners, LP | 2,614,402 | 6.45% | Schedule 13G, filed May 14, 2025 |
| JPMorgan Chase | 2,600,457 | 6.41% | Form 13F, quarter ended March 31, 2025 |
| Vanguard Group | 2,566,321 | 6.33% | Form 13F, quarter ended March 31, 2025 |
| Jasbir Seehra, Ph.D. | 1,717,969 | 4.24% | Proxy statement (DEF 14A), proxy filed April 23, 2025 |
| Morgan Stanley | 1,697,557 | 4.19% | Form 13F, quarter ended March 31, 2025 |
Percentages above are of 40,562,047 shares outstanding, as reported by KEROS THERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At KEROS THERAPEUTICS INC.'s shareholder meeting held June 4, 2025, in the 2024-2025 proxy season, 153 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 837 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers as… — KEROS THERAPEUTICS INC.'s filing reports the proposal as approved, with 82% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: KEROS THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 9, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from KEROS THERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
KEROS THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “KEROS THERAPEUTICS (KROS) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/keros-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.